Skip to content
Home
About Valeant
Key Facts and History
Board of Directors & Management
Corporate Governance
By-Laws
Governance Guidelines
Committee Structure
Committee Charters
Code of Business Conduct & Ethics
Other Ethical Disclosures
Sales & Marketing Compliance
Assistance Programs
Patient Assistance Program
Unrestricted Education Grants
Locations
Contact Us
Products & Pipeline
Dermatology
Acanya®
Atralin®
Cloderm®
Efudex/Efudix®
Oxsoralen-Ultra®
Tetrix®
Neurology and Other
DIASTAT® AcuDial™
Migranal®
Tasmar®
Zelapar®
Consumer Brands
Kinerase®
Nyal®
Bedoyecta®
CeraVe®
Dermatix™ Ultra
Dermadrate®
Dermaveen®
Branded Generics
Development Pipeline
Dermatology Pipeline
Neurology Pipeline
Media
Regional Expertise
Australia
Canada
Europe
Latin America
United States
Investor Relations
Stock Chart
News Releases
Financial Reports
Events & Presentations
Annual Reports
Analyst Coverage
SEC Filings
Advanced Fundamentals
Corporate Governance
Shareholder Services
Information Request
E-mail Alerts
Career Opportunities
Employee Benefits
Contact Us
Locations
Home
»
Investor Relations
»
Financial Reports
Investor Relations Home
Stock Chart
News Releases
Financial Reports
Events and Presentations
Annual Reports
Analyst Coverage
SEC Filings
Advanced Fundamentals
Corporate Governance
Shareholder Services
Information Request
E-mail Alerts
Financial Reports
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
May
May 05, 2009
Reconciliation of Product Sales and Revenue Excluding Acquisitions, Divestitures and Currency Impact For the Three Months Ended March 31, 2009 and 2008
